We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE...
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune...
-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical...
Cerecor to Acquire Aevi Genomic Medicine PR Newswire PHILADELPHIA, Dec. 5, 2019 PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (Nasdaq: GNMX) today announced that...
Aevi Genomic Medicine, Inc. Receives Positive Nasdaq Listing Determination PR Newswire PHILADELPHIA, Oct. 15, 2019 PHILADELPHIA, Oct. 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ:...
Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody Plan to enter Phase 2 in Adult Onset Still's Disease and other serious rare and orphan diseases PR...
Aevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare Conference PR Newswire PHILADELPHIA, Aug. 6, 2019 PHILADELPHIA, Aug. 6, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc...
Aevi Genomic Medicine Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor Entering Phase 2 clinical trials for the...
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders...
Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD PR Newswire PHILADELPHIA, Jan. 2, 2019 PHILADELPHIA, Jan...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | IX |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
